PMID- 29566387
OWN - NLM
STAT- MEDLINE
DCOM- 20180711
LR  - 20181114
IS  - 1423-0259 (Electronic)
IS  - 0030-3747 (Print)
IS  - 0030-3747 (Linking)
VI  - 60
IP  - 1
DP  - 2018
TI  - Spectral-Domain Optical Coherence Tomography-Driven Treat-and-Extend and Pro Re 
      Nata Regimen in Patients with Macular Oedema due to Retinal Vein Occlusion: 
      24-Month Evaluation and Outcome Predictors.
PG  - 29-37
LID - 10.1159/000487489 [doi]
AB  - PURPOSE: To analyse the efficacy and outcome predictors of ranibizumab using a 
      spectral-domain optical coherence tomography (SD-OCT)-driven treat-and-extend 
      regimen (TER) versus SD-OCT-driven pro re nata regimen (PRN) in patients with 
      cystoid macular oedema (CME) due to branch or central retinal vein occlusion 
      (BRVO, CRVO). METHODS: Retrospective, consecutive case series. Evaluation 
      included best corrected visual acuity (BCVA), morphological parameters on SD-OCT, 
      and treatment frequency. RESULTS: From baseline to months 12, 18, and 24, BCVA 
      improved by 16.6 +/- 13.1, 15.5 +/- 14.4, and 16.6 +/- 15.8 letters, respectively, in 
      TER (n = 45), compared to 11.3 +/- 17.0, 11.0 +/- 15.0, and 10 +/- 20.5 letters in PRN 
      (n = 31) (p = 0.152, p = 0.237, p = 0.172). The mean reduction in central retinal 
      thickness was -261 +/- 189, -272 +/- 188, and -264 +/- 158 mum, respectively, in TER, 
      compared to -130 +/- 196, -140 +/- 210, and -166 +/- 207 mum in PRN (p = 0.006, p = 
      0.017, p = 0.064). 59% (53%) of TER and 22% (17%) of PRN patients showed no 
      intra- or subretinal fluid on SD-OCT at 12 (24) months. Using TER, the maximum 
      recurrence-free treatment interval increased from 8.9 +/- 2.3 weeks at 12 months to 
      9.8 +/- 2.3 and 10.5 +/- 2.7 weeks at 18 and 24 months, respectively. The number of 
      injections was significantly higher in the TER than in the PRN group. 
      CONCLUSIONS: In CME, due to BRVO/CRVO, TER provides better morphological outcome 
      using more injections than PRN.
CI  - (c) 2018 The Author(s) Published by S. Karger AG, Basel.
FAU - Guichard, Maria-Magdalena
AU  - Guichard MM
AD  - Vista Klinik, Binningen, Switzerland.
FAU - Xavier, Anton R
AU  - Xavier AR
AD  - Vista Klinik, Binningen, Switzerland.
FAU - Turksever, Cengiz
AU  - Turksever C
AD  - Vista Klinik, Binningen, Switzerland.
FAU - Pruente, Christian
AU  - Pruente C
AD  - Department of Ophthalmology, University of Basel, Basel, Switzerland.
AD  - Department of Ophthalmology, Kantonsspital Liestal, Liestal, Switzerland.
FAU - Hatz, Katja
AU  - Hatz K
AD  - Vista Klinik, Binningen, Switzerland.
AD  - Department of Ophthalmology, University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20180322
PL  - Switzerland
TA  - Ophthalmic Res
JT  - Ophthalmic research
JID - 0267442
RN  - 0 (Angiogenesis Inhibitors)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Female
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/*drug therapy/etiology
MH  - Male
MH  - Middle Aged
MH  - Ranibizumab/*therapeutic use
MH  - Retinal Vein Occlusion/complications/*drug therapy
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence/*methods
MH  - Visual Acuity
PMC - PMC6050640
OTO - NOTNLM
OT  - Macular oedema
OT  - Pro re nata regimen
OT  - Ranibizumab
OT  - Retinal vein occlusion
OT  - Treat-and-extend regimen
EDAT- 2018/03/23 06:00
MHDA- 2018/07/12 06:00
PMCR- 2018/03/22
CRDT- 2018/03/23 06:00
PHST- 2017/11/22 00:00 [received]
PHST- 2018/02/07 00:00 [accepted]
PHST- 2018/03/23 06:00 [pubmed]
PHST- 2018/07/12 06:00 [medline]
PHST- 2018/03/23 06:00 [entrez]
PHST- 2018/03/22 00:00 [pmc-release]
AID - 000487489 [pii]
AID - ore-0060-0029 [pii]
AID - 10.1159/000487489 [doi]
PST - ppublish
SO  - Ophthalmic Res. 2018;60(1):29-37. doi: 10.1159/000487489. Epub 2018 Mar 22.